Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 26, 2017

DrugPatentWatch Database Preview

VYVANSE Drug Profile

« Back to Dashboard

What is the patent landscape for Vyvanse, and when can generic versions of Vyvanse launch?

Vyvanse is a drug marketed by Shire Dev Llc and Shire Development and is included in two NDAs. There are eighteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-two patent family members in twenty-six countries.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.

Summary for Tradename: VYVANSE

Patents:18
Applicants:2
NDAs:2
Suppliers / Packagers: see list4
Bulk Api Vendors: see list12
Clinical Trials: see list40
Patent Applications: see list30
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VYVANSE at DailyMed

Pharmacology for Tradename: VYVANSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-004Jan 28, 2017RXYesNo7,655,630► SubscribeYY ► Subscribe
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-003Feb 23, 2007RXYesYes7,659,253► SubscribeYY ► Subscribe
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-006Jan 28, 2017RXYesYes7,713,936► Subscribe ► Subscribe
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-003Feb 23, 2007RXYesYes7,700,561► SubscribeY ► Subscribe
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-003Jan 28, 2017RXYesNo7,678,771► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Analyze global market entry opportunities
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot